Science Current Events | Science News | Brightsurf.com
 

New analysis helps guide use of erlotinib in advanced non-small cell lung cancer

April 18, 2012

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.

The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.

In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.

"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.

"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to receive it as first line, as shown also in other trials," Dr Tsao said.

Patients with EGFR mutations benefit from the erlotinib-first regimen because their tumors are very sensitive to the anti-tumor activity of the drug, he explained.

"The take-home message from this study is that in advanced non-small cell lung cancer patients, treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or negative mutation status should be treated with the standard chemotherapy first."

Commenting on the study which he was not involved in, Dr Tetsuya Mitsudomi from Aichi Cancer Center Hospital in Nagoya, Japan, member of the IASLC Board of Directors, said: "Many previous trials, for instance IPASS, NEJ002, WJTOG3405, OPTIMAL, EUROTAC, have already shown that EGFR mutation is the most reliable predictive marker for EGFR-TKI treatment. The current paper was able to confirm the importance of EGFR mutation testing when considering the use of erlotinib, especially in consideration of the far shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib, this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting."

This biomarker analysis was preplanned but actually only 36% of the samples could be anlayzed for EGFR mutation. This relatively low tissue accrual rate is precedented by many clinical trials in which the mutation analysis was performed retrospectively. "Therefore, we also have to consider prospective determination of oncogene mutation when we want to raise this rate such as in NEJ, WJTOG, OPTIMAL and EUROTAC," Dr Mitsudomi added.

"In summary, the TORCH-BIO study adds imprortant evidence to the research field of EGFR-TKI in lung cancer and emphazizes the importance of biomarker study for improvement of clinical outcome."

European Society for Medical Oncology


Related Erlotinib Current Events and Erlotinib News Articles


Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival.

First precision medicine trial in cancer prevention identifies molecular-based chemoprevention strategy
A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

First precision medicine trial in cancer prevention identifies chemoprevention strategy
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

Multiple types of resistance to new lung cancer drug identified
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

SDSC/UCSD study uncovers mechanisms of cancer-causing mutations
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known "resistance" mutations in the gene called epidermal growth factor receptor (EGFR).

Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor (EGFR) mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology.

Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

Widely used osteoporosis drugs may prevent breast, lung and colon cancers
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences (PNAS).

Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.

Study May Explain Why Targeted Drug Doesn't Benefit Patients With Early-Stage Lung Cancer
The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene change, but when the same drug is used for patients with early-stage tumors with the same gene change, they actually fare worse than if they took nothing.
More Erlotinib Current Events and Erlotinib News Articles

Erlotinib: Webster's Timeline History, 2003 - 2007

Erlotinib: Webster's Timeline History, 2003 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Erlotinib," including when used in literature (e.g. all authors that might have Erlotinib in their name). As such, this book represents the largest compilation of timeline events associated with Erlotinib when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib


Background

Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive.

Methods and Findings

We sought to determine whether mutations in KRAS could be used to further enhance prediction of response to gefitinib or erlotinib. We screened 60 lung adenocarcinomas defined as sensitive or refractory to gefitinib or erlotinib for mutations in EGFR and KRAS. We show that mutations in KRAS are associated with a lack of sensitivity to either drug.
Protein Kinase Inhibitors in Research and Medicine, Volume 548 (Methods in Enzymology)

Protein Kinase Inhibitors in Research and Medicine, Volume 548 (Methods in Enzymology)
by Kevan M Shokat (Editor)


This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers protein kinase inhibitors in research and medicine, and includes chapters on such topics as fragment-based screening, broad kinome profiling of kinase inhibitors, and designing drug-resistant kinase alleles.Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization scienceContains sections focusing on protein kinase inhibitors in research and medicine

Top 100 Drug Interactions 2016: A Guide to Patient Management (Hansten, Top 100 Drug Interactions)

Top 100 Drug Interactions 2016: A Guide to Patient Management (Hansten, Top 100 Drug Interactions)
by Philip D. Hansten (Author), John R. Horn (Author)


This is the 17th yearly edition of The Top 100 Drug Interactions, with more than 300,000 copies in print since the first edition was published in 2000. In this book the authors attempt to identify drug interactions that should not be ignored in clinical practice. Management options are given for each interaction to offer the clinician actions that may be taken to reduce the risk of an adverse outcome. The book also contains a clinically useful and comprehensive table of drugs that are substrates, inhibitors or inducers of cytochrome P450 isozymes and ABC transporters.

Physicians' Cancer Chemotherapy Drug Manual 2016

Physicians' Cancer Chemotherapy Drug Manual 2016
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)


Completely revised and updated for 2016, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens―both on- and off-label―for the treatment of all the major cancers. SPECIAL FEATURES: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like belinostat, blinatumomab, lenvatinib, nivolumab, olaparib, palbociclib, panobinostat, pembrolizumab, and ramucirumab • A specific chapter focused on profiling antiemetic drugs and antiemetic treatment regimens. • Diagrams...

Skeel's Handbook of Cancer Therapy (Lippincott Williams & Wilkins Handbook)

Skeel's Handbook of Cancer Therapy (Lippincott Williams & Wilkins Handbook)
by Samir N. Khleif M.D. (Editor), Olivier Rixe MD PhD (Editor), Roland T Skeel M.D. (Editor)


For more than 30 years, Skeel’s Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the resource of choice for current, reliable information on cancer treatment for most adults. The 9th Edition reflects recent significant advances in the systemic treatment of cancer, including innovations in immunotherapy, oncology genomics, and molecular targeted therapy. An invaluable reference for all levels of physicians, nurses, and allied health professionals who provide care to cancer patients, this bestselling guide combines the most current rationale and the details necessary to safely administer pharmacologic therapy, offering a balanced synthesis between science and clinical practice.A new chapter on the Biologic Basis of Molecular Targeted Therapy, as well as a...

  Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
by Tom Brody PhD (Author)


Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understanding of how to conduct clinical trials. It will also act as a guide for the more experienced by detailing endpoint selection and illustrating how to avoid unnecessary pitfalls. This book is a...

Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams

Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams
by Francis P. Worden MD (Author), Anthony J. Perissinotti PharmD BCOP (Author), Bernard L. Marini PharmD (Author)


Cancer Pharmacology and Pharmacotherapy Reviewis the first book devoted entirely to providing the ‘must-know’ facts on each cancer agent—including their pharmacokinetics, FDA-approved indications,toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner toreview. The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portablestudy guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with...

Physicians' Cancer Chemotherapy Drug Manual 2015

Physicians' Cancer Chemotherapy Drug Manual 2015
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)


Completely revised and updated for 2015, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens―both on- and off-label―for the treatment of all the major cancers. SPECIAL FEATURES: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like afatinib, ceritinib, ibrutinib, idelalisib, obinutuzumab, and ramucirumab. • A specific chapter focused on profiling antiemetic drugs and antiemetic treatment regimens. • Diagrams of drug structures and pathways for many of...

Litt's Drug Eruption and Reaction Manual, 22nd Edition

Litt's Drug Eruption and Reaction Manual, 22nd Edition
by Jerome Z. Litt (Author)


Internationally relied upon by medical practitioners for its unparalleled focus on adverse effects and cutaneous reactions, Litt’s Drug Eruption & Reaction Manual is a succinct clinical reference and essential drug-safety tool for patient care. The new edition has been comprehensively revised and updated, featuring an enlarged section of tables for class reactions and new entries for recently licensed drugs. It has been comprehensively revised and updated throughout to act as a quick reference, and each entry includes: Summaries of numbers of reports and incidence for reactions Clinically important and potentially hazardous drug–drug interactions Categories of adverse drug reactions, eruptions, and cutaneous reaction patterns Essential reference information on prescription and...

© 2016 BrightSurf.com